DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 

 Monthly information regarding the total number of voting rights and

total number of shares of the Company as of October 31, 2021 

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

 

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345





Date



Total number of shares Total number of voting rights
10/31/202155,011,687



Total gross of voting rights: 55,011,687







Total net* of voting rights: 54,910,187



* Total net = total number of voting rights attached to shares – shares without voting rights

 

 

 

 

Attachment



EN
04/11/2021

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce la dernière visite du dernier patient dans l'...

DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides Châtillon, France, 12 novembre, 2025 DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides La société reste en bonne voie pour publier les données principales de VITESSE au quatrième trimestre de cette année DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nas...

November 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Pha...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the l...

November 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcar...

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts. A li...

November 4, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participera à la 2e conférence annuelle Guggenheim He...

DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation Châtillon, France, le 4 novembre (22 :30 CET) 2025 DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT— CUSIP : 23306J309), une société biopharmaceutique de stade clinique a annoncé ce jour que Daniel Tassé, Directeur Général, participera à une discussion « fireside chat » lors de la 2e conférence annuelle Guggenheim Healthcare Innovation le mardi 11 novembre à 14h00 (heure de l...

November 4, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commerc...

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial s...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch